Essential Thrombocythemia - 25 Studies Found
| Completed |
: A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia :
: 2009-03-17 : Drug: HDAC inhibitor (MK-0683) 400 mg once daily for 6 months |
| Completed |
: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera :
: 2010-11-11 : Drug: Imetelstat |
| Terminated |
: Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia :
: 2013-11-25 : Drug: Momelotinib Momelotinib tablet administered orally once daily |
| Completed |
: Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia :
: 2008-07-16 : Drug: LY573636-sodium Individualized dose is dependent on patient's height, weight, gender and is adjust |
| Active, not recruiting |
: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) :
|
| Active, not recruiting |
: Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia :
: 2008-07-29 : Drug: Ruxolitinib Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets. |
| Completed |
: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) :
|
| Completed |
: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia :
: 2015-03-24 :
|
| Completed |
: The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia :
: |
| Completed |
: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line : Essential Thrombocythemia : 2016-10-05 :
|